Marianne Pavel
University of Erlangen-Nuremberg
Internal medicineEndocrinologySurgeryPathologyOncologyAdverse effectPlaceboChemotherapyNeuroendocrine tumorsLanreotideEverolimusProgression-free survivalOctreotideCarcinoid syndromeTelotristat ethylIn patientClinical trialMedicineGastroenterology
308Publications
52H-index
12.1kCitations
Publications 295
Newest
#1Rajaventhan Srirajaskanthan (University of Cambridge)H-Index: 10
#2Marianne Pavel (FAU: University of Erlangen-Nuremberg)H-Index: 52
Last. Martin O. Weickert (Coventry Health Care)H-Index: 46
view all 7 authors...
Reported incidences of neuroendocrine tumors (NETs) appear to be increasing, possibly due to greater disease awareness and increased accuracy of diagnosis. Approximately 20% of patients with NETs develop carcinoid syndrome (CS), which arises from elevated secretion of bioactive compounds, including serotonin, from NETs. This leads to symptoms including diarrhea and flushing, which result in weight loss and are associated with considerable negative impact on patients' quality of life. We previous...
Source
#1Konstantinos Mantsopoulos (FAU: University of Erlangen-Nuremberg)H-Index: 17
#2Sarina K. Mueller (FAU: University of Erlangen-Nuremberg)H-Index: 11
Last. Heinrich Iro (FAU: University of Erlangen-Nuremberg)H-Index: 49
view all 8 authors...
Traditionally, the multimodal therapy concept for differentiated thyroid carcinomas consists of thyroidectomy with neck dissection (for cN + neck) and adjuvant radioiodine ablation with subsequent risk-adapted TSH suppression. The extent of radioiodine uptake in metastatic thyroid carcinomas plays a significant role is significant in terms of prognosis. Radioiodine refractory lesions are characterized by the lack of radioiodine uptake in combination with the lack of decrease in the tumor marker ...
Source
#1Eric Baudin (Institut Gustave Roussy)H-Index: 92
#2Martyn Caplin (Royal Free Hospital)H-Index: 71
Last. Ulrich Knigge (Copenhagen University Hospital)H-Index: 54
view all 17 authors...
Source
#1Marianne Pavel (FAU: University of Erlangen-Nuremberg)H-Index: 52
#2Jarosław B. Ćwikła (University of Warmia and Mazury in Olsztyn)H-Index: 23
Last. Aude Houchard (Ipsen)H-Index: 9
view all 11 authors...
Abstract null null Introduction null This prospective, single-arm, phase 2 study assessed the efficacy and safety of lanreotide autogel (LAN) administered at a reduced dosing interval in patients with progressive neuroendocrine tumours (NETs) after LAN standard regimen. null null null Methods null Patients had metastatic or locally advanced, grade 1 or 2 midgut NETs or pancreatic NETs (panNETs) and centrally assessed disease progression on LAN 120 mg every 28 days. They were treated with LAN 120...
Source
#1Clarisse Dromain (UNIL: University of Lausanne)H-Index: 60
#2M.P. Vullierme (University of Paris)H-Index: 4
Last. Kjell Öberg (Uppsala University)H-Index: 116
view all 14 authors...
This expert consensus document represents an initiative by the European Neuroendocrine Tumor Society (ENETS) to provide guidance for synoptic reporting of radiological examinations critical to the diagnosis, grading, staging and treatment of neuroendocrine neoplasms (NENs). Template drafts for initial tumor staging and follow-up by computed tomography (CT) and magnetic resonance imaging (MRI) were established, based on existing institutional and organisational reporting templates relevant for NE...
Source
Neuroendocrine neoplasms (NENs) represent a rare and heterogeneous group of malignancies, sharing features of both neural and endocrine cells. NENs G3 appear as a highly aggressive subset with poor prognosis and limited therapeutic options. The small-molecule inhibitor of the WEE1 tyrosine kinase, adavosertib (AZD1775), has previously demonstrated potent anti-tumor effects on various types of cancer in preclinical and clinical studies. However, the role of adavosertib in NENs G3 had remained elu...
Source
#4Martyn Caplin (Royal Free Hospital)H-Index: 71
Background: COVID-19 pandemic has added a degree of complexity in the management of patients with NET. We have little information about the real impact of COVID-19 in current practice. The aim of this study is to capture if and how COVID-19 is changing the way in which healthcare professionals treat NET patients. Methods: NET CONNECT taskforce designed an online anonymous survey addressing different aspects of NET. Survey was sent to nurses and physicians working in ENETS Centers of Excellence (...
Source
#1Philippe Ruszniewski (University of Paris)H-Index: 31
#2Martyn Caplin (Royal Free Hospital)H-Index: 71
Last. James C. Yao (University of Texas MD Anderson Cancer Center)H-Index: 74
view all 17 authors...
Source
#1Teodora KolarovaH-Index: 3
#2Mark McDonnellH-Index: 1
Last. Simone LeydenH-Index: 4
view all 14 authors...
Source
#1Uli Fehrenbach (Charité)H-Index: 5
#2Victor Rodriguez-Laval (Charité)H-Index: 1
Last. Timm Denecke (Charité)H-Index: 38
view all 6 authors...
BackgroundEverolimus, a mammalian target of rapamycin (mTOR)-inhibitor, is approved for the treatment of advanced neuroendocrine neoplasms (NEN). A rare major adverse event is the occurrence of dru...
Source